Alembic Pharma gets USFDA nod for depressive disorder drug
Alembic Pharma has recently received approval from USFDA to market its product which is a generic equivalent of Wyeth Pharma Inc's Pristiq tablets.
According to IQVIA, Desvenlafaxine extended-release tablets has a market size of around USD 13.3 million for twelve months ending December 2017.
Read Also: Alembic Pharma gets USFDA nod for an anti-depression drug
New Delhi: Alembic Pharma said it has received approval from the US health regulator to market Desvenlafaxine extended-release tablets, used to treat a major depressive disorder. The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Wyeth Pharma Inc's Pristiq tablets, Alembic Pharmaceuticals said in a regulatory filing.
According to IQVIA, Desvenlafaxine extended-release tablets has a market size of around USD 13.3 million for twelve months ending December 2017.
Read Also: Alembic Pharma gets USFDA nod for an anti-depression drug
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd